Day: February 21, 2022

PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED AUTHORIZATION TO FILE A NEW DRUG SUBMISSION FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) UNDER THE NOTICE OF COMPLIANCE WITH CONDITIONS (NOC/c) POLICY AB SCIENCE WILL HOST A WEBCAST TO PROVIDE DETAILS ON THIS APPLICATION AND AN UPDATE ON THE MASITINIB DEVELOPMENT PLAN Paris, 21 February, 2022, 5.45pm CET AB Science SA (Euronext – FR0010557264 – AB) today announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) under the Notice of Compliance with Conditions (NOC/c) policy. Market authorization under the NOC/c policy allows Health Canada to provide earlier market access to potentially life-saving drugs. NOC/c status is given to eligible drugs...

                                                                                                                                                                                                                                                                                                    Safe Orthopaedics announces the signature of an agreement with Brainlab for the development of navigation for Safe Orthopaedics instruments  Making Safe Orthopaedics instruments navigable with the Brainlab ecosystem Making minimally invasive surgery safe     Éragny-sur-Oise, February 21, 2022 at 5:45 p.m. CET – Safe (FR0013467123 – ALSAF), a company specializing in the design, manufacture and marketing of ready-to-use technologies for back surgery, particularly for the safe treatment of emergency vertebral fractures,...

                Paris, February 21st, 2022                                            Disclosure of transactions in own shares From February 14th to February 18th, 2022 Within the framework of the authorization granted by the General Meeting of VINCI SA of April 8, 2021 to trade in its shares and in accordance with the regulations relating to share buybacks, VINCI SA (LEI:213800WFQ334R8UXUG83) declares the purchases of treasury shares below (FR0000125486), carried out from February 14th to February 18th, 2022 :Aggregate presentation by day and by marketIssuer’s name Date of transaction Identifying code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares in Euro Market (MIC code)VINCI 14/02/2022 FR0000125486 59247 99,2395 XPARVINCI 14/02/2022 FR0000125486 31341 99,2645 CEUXVINCI 14/02/2022 FR0000125486 4716 99,2512 TQEXVINCI 14/02/2022 FR0000125486 4696 99,2798 AQEUVINCI 15/02/2022 FR0000125486 36935 100,9195 XPARVINCI 15/02/2022 FR0000125486 23065 100,8841 CEUXVINCI 16/02/2022 FR0000125486 25000 102,7248 XPARVINCI 17/02/2022 FR0000125486 31147 101,8124 XPARVINCI 18/02/2022 FR0000125486 30000 102,2266 XPARVINCI 18/02/2022 FR0000125486 20000 102,1849 CEUX               TOTAL 266...

PHILADELPHIA, Feb. 21, 2022 (GLOBE NEWSWIRE) — Carpenter Technology Corporation (NYSE: CRS), a leading producer and distributor of high-performance specialty alloy-based materials and process solutions for critical applications, today announced the following leadership updates. Brian Malloy has been named Senior Vice President and Group President of Carpenter Technology’s Performance Engineered Products (PEP) segment. In this role, Mr. Malloy will lead the PEP portfolio of businesses (Carpenter Additive, Dynamet Inc. and Carpenter Distribution) and related services. He will be responsible for leading PEP’s safety performance, driving growth, ensuring operational performance and enabling commercial excellence. In addition to leadership of the PEP segment, he will also lead the Company’s marketing organization and the Company’s electrification...

Bagsværd, Denmark, 21 February 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) as follows: Blackrock holds as of 15 February 2022 B shares equal to 4.98% of the entire share capital of Novo Nordisk. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to 5.00% of the entire share capital and below 5% of the voting rights. Blackrock holds as of 16 February 2022 B shares below 5% of the entire share capital of Novo Nordisk. The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments...

On 27 December 2022, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 10 of 21 December 2021. Under the programme, Schouw & Co. will acquire shares for up to DKK 350 million during the period 27 December 2021 to 30 December 2022. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount    Accumulated until 11/2/2022 112,252 562.22 63,110,497    Monday, 14 February 2022 6,200 567.09 3,515,958    Tuesday, 15 February 2022 0  –  –    Wednesday, 16 February 2022 132 582.00 76,824...

LONGWOOD, Fla., Feb. 21, 2022 (GLOBE NEWSWIRE) — U C, Inc., formerly named Symmetry Technologies, Inc. (OTC: SMMR), (the “Company”), announced today that, effective Feb. 14, 2022, it has appointed David Reckles as a new member to its Board of Directors, its Chief Executive Officer (“CEO”) and corporate Treasurer. During the past three years, Mr. Reckles has been active in the private label hemp and CBD manufacturing industries. Previously, he spent 20+ years in corporate America as a Chief Technologist and CTO for companies such as American Airlines, AT Kearney, BP, Dell, Dow, EDS, Gap, Pfizer, and United Airlines. He additionally served HP/EDS as an Enterprise Architect and Chief Technologist for many client and company initiatives, with particular emphasis on Information Technology Innovation, automation,...

AB “Ignitis grupė” (hereinafter – the Group) informs that its subsidiary UAB “Ignitis renewables” (hereinafter – Ignitis renewables) terminatined the conditional SPA agreement to acquire up to 170 MW portfolio of solar PV projects under development (Polish solar portfolio I) in Poland. The Group and Ignitis renewables will suffer no loss in respect of this transaction. Ignitis renewables on 21 February terminated agreement with developer Sun Investment Group by mutual consent. The agreement terminated due to no projects being awarded CfD tariff in the last auctions. Over the last six months we held agreement renegotiations with the developer. As no agreement regarding acceptable return level which would be in line with our target range (high single-digit to low double-digit return) was reached, the conditional SPA agreement was terminated. Advance...

AB “Ignitis grupė” (hereinafter – the Group) informs that its subsidiary UAB “Ignitis renewables” (hereinafter – Ignitis renewables) terminatined the conditional SPA agreement to acquire up to 170 MW portfolio of solar PV projects under development (Polish solar portfolio I) in Poland. The Group and Ignitis renewables will suffer no loss in respect of this transaction. Ignitis renewables on 21 February terminated agreement with developer Sun Investment Group by mutual consent. The agreement terminated due to no projects being awarded CfD tariff in the last auctions. Over the last six months we held agreement renegotiations with the developer. As no agreement regarding acceptable return level which would be in line with our target range (high single-digit to low double-digit return) was reached, the conditional SPA agreement was terminated. Advance...